Bylvay™
Bylvay is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
Option 1: e-prescribe
Frontier Therapies II - Optum
6425 Santa Margarita St. #110
Las Vegas, NV 89118
NABP: 788638
NPI: 1720364532
NCPDP: 2992750
Option 2: fax
Send the appropriate therapy forms and documentation to 1-866-991-9929.
Option 3: call
Discuss the process, understand how to submit documentation, or place an order by calling us at 1-855-768-9727.
Therapies and forms
Find out more about the therapies we dispense below. Select Find forms to access the appropriate therapy enrollment forms and documentation.
B
F
FILSPARI™
FILSPARI (sparsentan) is an endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ration (UPCR) ≥1.5 g/g.
K
Kuvan™
Kuvan is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.
L
LUMRYZ™
LUMRYZ is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
N
NITYR®
NITYR® is a hydroxyphenyl-pyruvate dioxygenase inhibitor used to treat adults and children with hereditary tyrosinemia type 1 (HT-1). NITYR works by preventing the body from breaking down an amino acid called tyrosine and by keeping other toxic substances from building up and causing harm to liver or kidneys.
P
Palynziq™
Palynziq is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.
Q
QalsodyTM
QALSODYTM (tofersen) is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
R
REBYOTA
REBYOTA™ is a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
RELYVRIO™
RELYVRIO™ (sodium phenylbutyrate and taurusodiol) powder for oral suspension is approved for the treatment of ALS
S
Sucraid®
Sucraid® is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).
V
VOXZOGO™
VOXZOGO™ is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.
Top